Dose-response relationship between exercise interventions and quality of life in older adults with cancer: A systematic review and meta-analysis.

J Geriatr OncolJul 2, 2026 (epub)
Clinical ResearchGeriatricsOncology (Medical)

Yaxin Wang, Ziqi Gao, Huimin Yang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of exercise interventions on quality of life in 2557 older adults with cancer. The analysis revealed a significant improvement in quality of life (SMD = 0.27, 95% CI: 0.14-0.41) associated with exercise, with optimal benefits observed at a weekly volume of approximately 962.94 MET·min/week.

Key findings

  • Exercise interventions improved quality of life with an SMD of 0.27 (95% CI: 0.14-0.41).
  • Greater improvements were noted with interventions lasting 8-12 weeks (SMD = 0.37, 95% CI: 0.19-0.56).
  • A frequency of three sessions per week yielded an SMD of 0.36 (95% CI: 0.18-0.54).
  • Optimal quality of life improvements were linked to a weekly exercise volume of approximately 962.94 MET·min/week (Hedges' g = 0.41).

Why it matters

Understanding the relationship between exercise and quality of life in older cancer patients can guide clinicians in recommending tailored exercise programs, potentially enhancing patient well-being during treatment.

Source

PubMed · PMID 42391992

Published in J Geriatr Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.